



EAACI
EUROPEAN ACADEMY OF ALLERGY
AND CLINICAL IMMUNOLOGY


EAACI Allergy School 2025
Biologicals, type 2 inflammation and
eosinophil-associated diseases

 **4 - 6 September**

 **Florence, Italy**



eaaci.org



Thursday 4 September

EAACI AS Florence 2025

Thu 4 Sep
12:00 - 13:45 | **REGISTRATION**
Break & Ceremony

Thu 4 Sep
13:45 - 14:15 | **OPENING CEREMONY**
Room IL, Ground Floor Break & Ceremony

13:45 **OPENING CEREMONY**
Maria Torres (Malaga, Spain), Alessandra Vultaggio (Florence, Italy), Andrea Matucci (Florence, Italy)

Thu 4 Sep
14:15 - 15:45 | **SESSION 1 – THE BASIS: IMMUNOLOGICAL PATHWAYS OF TYPE 2 INFLAMMATION**
Room IL, Ground Floor Lecture

Chair : Stefano Del Giacco (Cagliari, Italy), Leticia de las Vecillas Sanchez (Madrid, Spain)

To understand the importance of different cytokines and the role of different cells in driving local and systemic type 2 inflammation and in the progression of type 2 diseases

14:15 **IL-4, IL-13 and IgE pathways**
Oscar Palomares (Madrid, Spain)

14:40 **IL-5 and eosinophils**
Alessandra Vultaggio (Florence, Italy)


15:05 **Epithelial barrier and epithelial cytokines**
Ibon Eguiluz (Malaga, Spain)

15:30 **Q&A**

Thu 4 Sep
15:45 - 16:15 | **COFFEE BREAK**
Room ABCD, First Floor Break & Ceremony

Thu 4 Sep
16:15 - 16:45 | **Industry Session 1**
Room IL, Ground Floor Industry Session

Please visit the "Sponsorship & Exhibition" section on the event page for further details



Thu 4 Sep 16:45 - 18:20

SESSION 2 – BIOLOGICALS FOR TYPE 2-MEDIATED DISEASES

Room IL, Ground Floor Lecture

Chair : Constantinos Pitsios (Nicosia, Cyprus), Massimo Triggiani (Salerno, Italy)

To discuss how different cytokines and molecules can be targeted in the treatment of different type 2 diseases

16:45 Biologicals targeting IgE pathway

Thomas Eiwegger (St. Poelten, Austria)

17:05 Biologicals targeting IL-5 pathway

Andrea Matucci (Florence, Italy)

17:25 Biologicals targeting IL-4/IL-13 pathway

Stefano Del Giacco (Cagliari, Italy)

17:45 Biologicals targeting TSLP pathway

Leticia de las Vecillas Sanchez (Madrid, Spain)

18:05 Q&A

Thu 4 Sep 18:20 - 18:50

ORAL PRESENTATION SESSION 1

Room IL, Ground Floor Oral Presentation

Chair : Thomas Eiwegger (St. Poelten, Austria), Andrea Matucci (Florence, Italy)

18:20 Dysregulated Airway Mucins: Triggers of Local and Systemic Inflammation

OAS 1

Neeraj Patil (Gothenburg, Sweden)

18:30 NLRP3 Inhibition with MCC950: A Promising Approach to Reduce Mucus Production and Improve Epithelial Function in Airway Inflammation

OAS 2

Behnoush NASR ZANJANI (Istanbul, Türkiye)

18:40 AllergoOncology: Non-allergic urticarial skin reactions associated with MOv18 IgE, a first-in-class IgE antibody recognizing Folate Receptor alpha (FR α)


OAS 3

Jitesh Chauhan (London, United Kingdom)

Thu 4 Sep 18:50 - 19:50

WELCOME COCKTAIL

Room ABCD, First Floor Break & Ceremony



 Friday 5 September

EAACI AS Florence 2025

Fri 5 Sep
08:30 - 10:00 | **SESSION 3 – TREATING T2 INFLAMMATION IN AIRWAYS**
Room IL, Ground Floor Lecture

Chair : Andrea Matucci (Florence, Italy), Thomas Eiwegger (St. Poelten, Austria)

To explore how biologicals with different mechanism of actions may affect upper and lower airway inflammation in both adults and children

08:30 | **Biologicals in T2 adult asthma**

Santiago Quirce (Madrid, Spain)

08:55 | **Biologicals in T2 chronic rhinosinusitis with nasal polyps**

Joaquim Mullol (Barcelona, Spain)

09:20 | **Biological in T2 pediatric asthma**

Mattia Giovannini (Florence, Italy)

09:45 | **Q&A**

Fri 5 Sep
10:00 - 10:30 | **Industry Session 2**
Room IL, Ground Floor Industry Session

Please visit the "Sponsorship & Exhibition" section on the event page for further details

Fri 5 Sep
10:30 - 11:00 | **COFFEE BREAK**
Room ABCD, First Floor Break & Ceremony

Fri 5 Sep
11:00 - 12:30 | **SESSION 4 – Type 2 inflammation and skin disorders**
Room IL, Ground Floor Lecture

Chair : Ibon Eguiluz (Malaga, Spain), Mattia Giovannini (Florence, Italy)

To discuss about the clinical and therapeutic relevance of type 2 inflammation in allergic skin disorders

11:00 | **Treatment of chronic urticaria**

Massimo Triggiani (Salerno, Italy)


11:25 | **Therapeutic approaches for atopic dermatitis**

Francesca Prignano (Florence, Italy)

11:50 | **Drug-induced hypereosinophilia: diagnosis and management**

Maria Torres (Malaga, Spain)

12:15 | **Q&A**



Fri 5 Sep 12:30 - 13:00

ORAL PRESENTATION SESSION 2

Room IL, Ground Floor Oral Presentation

Chair : Alessandra Vultaggio (Florence, Italy), Oscar Palomares (Madrid, Spain)

12:30 OAS 4

Frequency of eosinophil subgroups varies by inflammatory context in experimental mouse models of asthma

Hiba Sayedali (Gothenburg, Sweden)

12:40 OAS 5

Prognostic role of CD62Llow inflammatory eosinophils in asthma severity and their importance in mepolizumab response prediction

Matteo Accinno (Florence, Italy)

12:50 OAS 6

BBT002: A Novel Tetraivalent Bispecific Antibody Targeting IL4Ra and IL5 Demonstrates Potential to Improve Asthma Treatment Outcomes

Shanshan Xu (Boston, United States of America)

Fri 5 Sep 13:00 - 14:00

LUNCH

Breakfast Area "The Florentine" & Restaurant "Luci Della Città", First Floor Break & Ceremony

Fri 5 Sep 14:00 - 15:30

SESSION 5 – TYPE 2 INFLAMMATION IN FOOD ALLERGY

Room IL, Ground Floor Lecture

Chair : Maria Torres (Malaga, Spain), Andrea Matucci (Florence, Italy)

To explore how type 2 inflammation may be associated with different clinical manifestation in GI tract

14:00

IgE-mediated food allergy

Thomas Eiwegger (St. Poelten, Austria)

14:25

Management of food-induced anaphylaxis

Mattia Giovannini (Florence, Italy)

14:50

Biologicals in Food Allergy

Thomas Eiwegger (St. Poelten, Austria)


15:15

Q&A

Fri 5 Sep 15:30 - 16:00

Coffee Break

Room ABCD, First Floor Break & Ceremony



Fri 5 Sep
16:00 - 16:30 | **ORAL PRESENTATION SESSION 3**
Room IL, Ground Floor Oral Presentation

Chair : Leticia de las Vecillas Sanchez (Madrid, Spain), Joaquim Mullol (Barcelona, Spain)


16:00
OAS 7 | **Distinct Cytokine Signatures in Nasal Lavage of Patients with Aspirin-Exacerbated Respiratory Disease**
Piotr Szatkowski (Kraków, Poland)

16:10
OAS 8 | **Dupilumab is Efficacious in Children With Eosinophilic Esophagitis Irrespective of Individual Atopic Comorbidities: 16-Week Results From the Phase 3 EoE KIDS Study**
Mirna Chehade (New York, United States of America)

16:20
OAS 9 | **Identification of Noninvasive Biomarkers of Pediatric Eosinophilic Esophagitis**
Martina Votto (Benevento, Italy)

Fri 5 Sep
16:30 - 16:40 | **INTRODUCTION TO THE WORKSHOP SESSION AND INSTRUCTIONS FOR PARTICIPANTS**
Practical Workshop

Chair : Alessandra Vultaggio (Florence, Italy)



Fri 5 Sep 16:40 - 18:00

TOPIC 1: Asthma, CRSwNPs and EGPA - Subgroup 1

Room ABCD, First Floor Poster Discussion

Chair : Andrea Matucci (Florence, Italy), Oscar Palomares (Madrid, Spain)

16:40 P01

The impact of type 1, type 2, and type 3 inflammation on airway epithelial cells

Emilia Åkesson (Gothenburg, Sweden)

16:45 P05

"Biologics and smell recovery"

Karolina Frachowicz-Guerreiro (Łódź, Poland)

16:50 P06

A Novel Combined Approach: Dupilumab-Induced Tolerance Facilitating Subcutaneous Immunotherapy in Severe Asthma

Sofía Gómez De La Cruz Pérez (Córdoba, Spain)

16:55 P07

The Significance of Eosinophil Location in Severe Asthma and Insights from Induced Sputum: A Case Report

Anja Ilovor Bezjak (Golnik, Slovenia)

17:00 P08

Mepolizumab 100 mg for EGPA: Efficacy in Managing Concomitant Severe Asthma

Francesca Mascia (Verona, Italy)

17:05 P09

Real-life evaluation of biologicals in severe T2 asthma: a study of the BIOBADALER Consortium

Beatriz De Fátima Moya-Seseña (Málaga, Spain)

17:10 P10

Dupilumab and Tezepelumab – A Head-to-Head Comparison of Clinical Effectiveness and Type 2 Biomarker Changes in Severe Asthma Patients

Krzysztof Olesiejuk (Łódź, Poland)

17:15 P11


Persistent remission of chronic rhinosinusitis with nasal polyps after dupilumab discontinuation: a case report

Bianca Olivieri (Verona, Italy)

17:20 P12

Tapering of Biologicals in CRSwNP – a Nationwide RCT

Elizabeth M. Stevens (Copenhagen, Denmark)



Fri 5 Sep
16:40 - 18:00

TOPIC 1: Asthma, CRSwNPs and EGPA - Subgroup 2

Room ABCD, First Floor Poster Discussion

Chair : Santiago Quirce (Madrid, Spain), Alessandra Vultaggio (Florence, Italy)

16:40
P14 **Molecular predictors of allergen-specific immunotherapy efficacy in patients with year-round rhinitis and sensitization to house dust mites**

Vladyslav Tsaryk (Kyiv, Ukraine)

16:45
P16 **Pericarditis Associated with dupilumab-Induced Eosinophilia: A Case Report**

Nika Kotnik (Golnik, Slovenia)

16:50
P17 **Analysis of possible factors associated with resolution of fixed obstruction after treatment with monoclonal antibody for severe asthma**

Andrea Giovanni Ledda (Cagliari, Italy)

16:55
P18 **Preliminary evaluation of a cohort of Italian patients that experienced switching biologics in asthma**

Eleonora Piano (Cagliari, Italy)

17:00
P19 **An atypical case of hypereosinophilia**

Saša Rink (Ljubljana, Slovenia)

17:05
P20 **Early-Onset Eosinophilic Granulomatosis with Polyangiitis (EGPA) in an 18-Year-Old: Successful Treatment with Benralizumab**

Milica Terzić (Belgrade, Serbia)

17:10
P21 **Effectiveness of Reslizumab in the Management of Severe Eosinophilic Asthma: Experience from a Single Centre**


Milica Terzić (Belgrade, Serbia)

17:15
P23 **Prevalence of T2 asthma in the elderly population**

Martyna Miodonska (Zabrze, Poland)

17:20
P24 **Benralizumab in a patient with severe mixed-phenotype asthma after failure of previous biologics: a case report**

Dominika Ochab-Krupnik (Chęciny, Poland)



Fri 5 Sep
16:40 - 18:00

TOPIC 2: Food allergy and EoE

Room ABCD, First Floor Poster Discussion

Chair : Thomas Eiwegger (St. Poelten, Austria), Constantinos Pitsios (Nicosia, Cyprus)

16:40
P25 **Upadacitinib as a Successful Therapeutic Option for Kimura's Disease Associated with Ulcerative Colitis: A Case Report**
Aseel Almasoudi (Riyadh, Saudi Arabia)

16:45
P26 **Evaluation of NKT cells in iHES syndrome**
Marco Zurlo (Verona, Italy)

16:50
P27 **Renal disease and Eosinophilia :An atypical case**
Florida Dogjani (Tirana, Albania)

16:55
P29 **Complex diagnosis, clear outcome: Successful anti-IL-5R therapy in overlapping eosinophilic disease**
Natasa Kusic (Belgrade, Serbia)


17:00
P30 **Patterns of Organ Involvement and Allergy Burden in Hypereosinophilic Syndrome- insights from a centralized reference centre**
Piotr Lacwik (Chęciny, Poland)

17:05
P32 **Burned Out Eosinophilic Esophagitis: A New Concept in the Progression of Untreated Eosinophilic Esophagitis**
Adhora Mir (Montréal, Canada)

17:10
P33 **Biologic–AIT Combination Therapy as a Successful Treatment for Refractory Eosinophilic Esophagitis in a 12-Year-Old Boy with Allergic Rhinitis and Asthma: A Case Report**
Marta Navratil (Zagreb, Croatia)

17:15
P35 **Severe Cow's Milk Anaphylaxis in Children: A Case Series Supporting the Role of Allergen Avoidance and Biologic Therapy Assessment**
Cristhel Puente (Jesús María, Peru)

17:20
P36 **Edible insects:crick or treat?**
Marina Curci (Roma, Italy)



Fri 5 Sep
16:40 - 18:00

TOPIC 3: Skin disorders

Room ABCD, First Floor Poster Discussion

Chair : Ibon Eguiluz (Malaga, Spain), Francesca Prignano (Florence, Italy)

16:40 P37 **Transcriptomic Insights into Dupilumab Response in Netherton Syndrome with Dual SPINK5 and FLG Mutations**

Cristina Bajo Santos (Salamanca, Spain)

16:45 P38 **Evaluating Antihistamine Discontinuation in Patients Receiving Omalizumab for Chronic Spontaneous Urticaria: A Study of the BIOBADALER Consortium**

Paola Leonor Quan (Pamplona, Spain)

16:50 P39 **TH-2 monoclonals and JAK-inhibitors to treat IEL with allergic dysregulation: the ATO-PID project**

Germano Sardella (Cerveteri, Italy)

16:55 P40 **Impact of Selected Adverse Effects on the Effectiveness of Severe Atopic Dermatitis Treatment – Prospective Analysis**

Urszula Jedynak-Wąsowicz (Kraków, Poland)

17:00 P43 **Access Barriers to Biologic Therapies for Immune-Mediated Diseases in Albania: A Situational Analysis**

Antonela Simaku (Tiranë, Albania)

17:05 P44 **Biological induced conjunctivitis in atopic dermatitis is associated with decreased inflammatory mediators in tears: a study of the BIOBADALER Consortium**

Laura Zubiaga Fernández (Málaga, Spain)

17:10 P45 **Benralizumab in steroid-refractory DRESS - a single center case series**

Maria Elena Milanese (Florence, Italy)

17:15 P48 **Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome secondary to amoxicillin with clavulanic acid: a case report**

Diana Meter (Split, Croatia)

17:20 P49 **Allergic comorbidities in children with chronic urticaria**

AIKATERINI PETTA (Athens, Greece)

17:25 P50 **Exacerbated mastoiditis with autoimmune inflammation under ocrelizumab treatment**

Klaudia Wachal (München, Germany)

17:30 P51 **A versatile monoclonal antibody: three case reports of uncommon use and efficacy of Dupilumab**


Martina Bullita (Cagliari, Italy)

17:35 P52 **Allopurinol-Induced DRESS Complicated by VBDS: A Case Report**

Aseel Almasoudi (Riyadh, Saudi Arabia)

17:40 P53 **Case Report: Steroid Resistant Bullous Pemphigoid And Hyper-Eosinophilic Syndrome: New Therapeutic Approaches And Therapeutic Challenges**

Marco Zurlo (Verona, Italy)



Fri 5 Sep
19:20 - 22:30

DINNER

Cecchini in città Break & Ceremony

Please refer to the final logistics information received via email from education@eaaci.org for details

19:20 Meeting at the foyer of DoubleTree by Hilton Florence for the bus transfer

19:30 Bus boarding and departure

20:00 Dinner at "Ceccini in Città"

22:00 Transfer back to the Hotel

📅 Saturday 6 September

EAACI AS Florence 2025

Sat 6 Sep
08:20 - 10:30

Workshop: Green Group

Room H, Ground Floor Practical Workshop

To discuss hot topics in type 2 and eosinophilic-associated diseases informally, with experts in the field, starting from clinical cases

- *Workshop 1: to explore the usefulness of different clinical, laboratory and functional biomarkers in the selection of type 2 biologicals*
- *Workshop 2: to evaluate the safety profile of T2 biologicals currently used in adults and children*
- *Workshop 3: case-based discussion of the differential diagnosis of hypereosinophilia*

**Sessions will run simultaneously in rotation across three rooms, ensuring that each attendee has the opportunity to attend all sessions. Participants will be divided into three groups, identified by color: Red, Green, and Yellow.*

08:20 Workshop 1: Clinical corner: What drives the direction of treatment choice in asthma and CRSwNP?

Stefano Del Giacco (Cagliari, Italy), Santiago Quirce (Madrid, Spain)

09:00 Rotation time for speakers


09:05 Workshop 2: Clinical corner: Safety of anti-T2 biologicals

Alessandra Vultaggio (Florence, Italy), Ibon Eguiluz (Málaga, Spain)

09:45 Rotation time for speakers

09:50 Workshop 3: Clinical Corner: Diagnostic approach to high blood eosinophil count

Giovanni Martinelli (Bologna, Italy), Thomas Eiwegger (St. Poelten, Austria)



Sat 6 Sep
08:20 - 10:30

Workshop: Red Group

Room I, Ground Floor Practical Workshop

To discuss hot topics in type 2 and eosinophilic-associated diseases informally, with experts in the field, starting from clinical cases

- *Workshop 1: to explore the usefulness of different clinical, laboratory and functional biomarkers in the selection of type 2 biologicals*
- *Workshop 2: to evaluate the safety profile of T2 biologicals currently used in adults and children*
- *Workshop 3: case-based discussion of the differential diagnosis of hypereosinophilia*

**Sessions will run simultaneously in rotation across three rooms, ensuring that each attendee has the opportunity to attend all sessions. Participants will be divided into three groups, identified by color: Red, Green, and Yellow.*

08:20 Workshop 2: Clinical corner: Safety of anti-T2 biologicals

Alessandra Vultaggio (Florence, Italy), Ibon Eguluz (Málaga, Spain)

09:00 Rotation time for speakers

09:05 Workshop 3: Clinical Corner: Diagnostic approach to high blood eosinophil count

Giovanni Martinelli (Bologna, Italy), Thomas Eiwegger (St. Poelten, Austria)

09:45 Rotation time for speakers

09:50 Workshop 1: Clinical corner: What drives the direction of treatment choice in asthma and CRSwNP?

Stefano Del Giacco (Cagliari, Italy), Santiago Quirce (Madrid, Spain)

Sat 6 Sep
08:20 - 10:30

Workshop: Yellow Group

Room L, Ground Floor Practical Workshop

To discuss hot topics in type 2 and eosinophilic-associated diseases informally, with experts in the field, starting from clinical cases

- *Workshop 1: to explore the usefulness of different clinical, laboratory and functional biomarkers in the selection of type 2 biologicals*
- *Workshop 2: to evaluate the safety profile of T2 biologicals currently used in adults and children*
- *Workshop 3: case-based discussion of the differential diagnosis of hypereosinophilia*

**Sessions will run simultaneously in rotation across three rooms, ensuring that each attendee has the opportunity to attend all sessions. Participants will be divided into three groups, identified by color: Red, Green, and Yellow.*

08:20 Workshop 3: Clinical Corner: Diagnostic approach to high blood eosinophil count

Giovanni Martinelli (Bologna, Italy), Thomas Eiwegger (St. Poelten, Austria)

09:00 Rotation time for speakers


09:05 Workshop 1: Clinical corner: What drives the direction of treatment choice in asthma and CRSwNP?

Stefano Del Giacco (Cagliari, Italy), Santiago Quirce (Madrid, Spain)

09:45 Rotation time for speakers

09:50 Workshop 2: Clinical corner: Safety of anti-T2 biologicals

Alessandra Vultaggio (Florence, Italy), Ibon Eguluz (Málaga, Spain)



Sat 6 Sep
10:30 - 11:00

COFFEE BREAK

Room ABCD, First Floor Break & Ceremony

Sat 6 Sep
11:00 - 12:30

SESSION 6: TYPE 2 INFLAMMATION IN RARE DISEASES

Room IL, Ground Floor Lecture

Chair : Ozlem Ceylan (Istanbul, Türkiye), Joaquim Mullol (Barcelona, Spain)

To review the involvement of Type 2 cytokines and type 2 immune response in several rare diseases, opening novel therapeutic strategies

11:00

How to diagnose HES?

Giovanni Martinelli (Bologna, Italy)

11:25

Diagnosis and Treatment of EGPA

Andrea Matucci (Florence, Italy)

11:50

Type 2 inflammation and EoE

Constantinos Pitsios (Nicosia, Cyprus)

12:15

Q&A

Sat 6 Sep
12:30 - 12:50

CLOSING REMARKS

Room IL, Ground Floor Break & Ceremony

12:30

CLOSING REMARKS

Alessandra Vultaggio (Florence, Italy), Andrea Matucci (Florence, Italy), Ozlem Ceylan (Istanbul, Türkiye)